BACKGROUND: Since the clinical impact of sarcopenia on multimodal therapy for patients with esophageal cancer is not well understood, this study was conducted to determine the influence of sarcopenia on the efficacy of neoadjuvant chemoradiotherapy (NACRT) for locally advanced esophageal cancer. METHODS: The skeletal muscle index was quantified at the level of the third lumbar vertebra on computed tomography images, and sarcopenia was defined as a skeletal muscle index that was less than the average for each gender. We compared treatment outcomes in patients with cT3 and nearly T4 thoracic esophageal squamous cell carcinoma between the sarcopenia group (n = 85) and the non-sarcopenia group (n = 72). RESULTS: The 5-year survival rates were 33.4% in the non-sarcopenia group and 31.5% in the sarcopenia group; these differences were not significant. The prognosis of the patients with sarcopenia was worse than that of the patients without sarcopenia in the surgery-alone group, but there was no difference between patients with and without sarcopenia in the NACRT group. CONCLUSIONS: NACRT could be a useful option for patients with locally advanced esophageal squamous cell carcinoma, even for those with sarcopenia, without increasing the incidence of morbidity and mortality.
BACKGROUND: Since the clinical impact of sarcopenia on multimodal therapy for patients with esophageal cancer is not well understood, this study was conducted to determine the influence of sarcopenia on the efficacy of neoadjuvant chemoradiotherapy (NACRT) for locally advanced esophageal cancer. METHODS: The skeletal muscle index was quantified at the level of the third lumbar vertebra on computed tomography images, and sarcopenia was defined as a skeletal muscle index that was less than the average for each gender. We compared treatment outcomes in patients with cT3 and nearly T4 thoracic esophageal squamous cell carcinoma between the sarcopenia group (n = 85) and the non-sarcopenia group (n = 72). RESULTS: The 5-year survival rates were 33.4% in the non-sarcopenia group and 31.5% in the sarcopenia group; these differences were not significant. The prognosis of the patients with sarcopenia was worse than that of the patients without sarcopenia in the surgery-alone group, but there was no difference between patients with and without sarcopenia in the NACRT group. CONCLUSIONS:NACRT could be a useful option for patients with locally advanced esophageal squamous cell carcinoma, even for those with sarcopenia, without increasing the incidence of morbidity and mortality.
Authors: K Harada; S Ida; Y Baba; T Ishimoto; K Kosumi; R Tokunaga; D Izumi; M Ohuchi; K Nakamura; Y Kiyozumi; Y Imamura; M Iwatsuki; S Iwagami; Y Miyamoto; Y Sakamoto; N Yoshida; M Watanabe; H Baba Journal: Dis Esophagus Date: 2015-06-30 Impact factor: 3.429
Authors: J Arends; G Bodoky; F Bozzetti; K Fearon; M Muscaritoli; G Selga; M A E van Bokhorst-de van der Schueren; M von Meyenfeldt; G Zürcher; R Fietkau; E Aulbert; B Frick; M Holm; M Kneba; H J Mestrom; A Zander Journal: Clin Nutr Date: 2006-05-12 Impact factor: 7.324
Authors: Christopher E Avendano; Patrick A Flume; Gerard A Silvestri; Lydia B King; Carolyn E Reed Journal: Ann Thorac Surg Date: 2002-03 Impact factor: 4.330
Authors: Alfonso J Cruz-Jentoft; Jean Pierre Baeyens; Jürgen M Bauer; Yves Boirie; Tommy Cederholm; Francesco Landi; Finbarr C Martin; Jean-Pierre Michel; Yves Rolland; Stéphane M Schneider; Eva Topinková; Maurits Vandewoude; Mauro Zamboni Journal: Age Ageing Date: 2010-04-13 Impact factor: 10.668
Authors: F Fiorica; D Di Bona; F Schepis; A Licata; L Shahied; A Venturi; A M Falchi; A Craxì; C Cammà Journal: Gut Date: 2004-07 Impact factor: 23.059
Authors: Connie Yip; Vicky Goh; Andrew Davies; James Gossage; Rosalind Mitchell-Hay; Orla Hynes; Nick Maisey; Paul Ross; Andrew Gaya; David B Landau; Gary J Cook; Nyree Griffin; Robert Mason Journal: Eur Radiol Date: 2014-02-18 Impact factor: 5.315
Authors: Linda B M Weerink; Anouk van der Hoorn; Barbara L van Leeuwen; Geertruida H de Bock Journal: J Cachexia Sarcopenia Muscle Date: 2020-03-03 Impact factor: 12.910
Authors: Lucy X Ma; Kirsty Taylor; Osvaldo Espin-Garcia; Reut Anconina; Chihiro Suzuki; Michael J Allen; Marta Honorio; Yvonne Bach; Frances Allison; Eric X Chen; Savtaj Brar; Carol J Swallow; Jonathan Yeung; Gail E Darling; Rebecca Wong; Sangeetha N Kalimuthu; Raymond W Jang; Patrick Veit-Haibach; Elena Elimova Journal: Cancer Med Date: 2020-12-09 Impact factor: 4.452
Authors: Josh McGovern; Ross D Dolan; Paul G Horgan; Barry J Laird; Donald C McMillan Journal: J Cachexia Sarcopenia Muscle Date: 2021-10-18 Impact factor: 12.910